These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24683126)

  • 1. Gait changes with anti-dementia drugs: a prospective, open-label study combining single and dual task assessments in patients with Alzheimer's disease.
    Beauchet O; Launay CP; Allali G; Herrmann FR; Annweiler C
    Drugs Aging; 2014 May; 31(5):363-72. PubMed ID: 24683126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study.
    Beauchet O; Launay CP; Allali G; Watfa G; Gallouj K; Herrmann FR; Annweiler C
    BMC Neurol; 2013 Nov; 13():184. PubMed ID: 24261605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Dementia Drugs, Gait Performance and Mental Imagery of Gait: A Non-Randomized Open-Label Trial.
    Beauchet O; Barden J; Liu-Ambrose T; Chester VL; Annweiler C; Szturm T; Grenier S; Léonard G; Bherer L; Allali G;
    Drugs Aging; 2016 Sep; 33(9):665-73. PubMed ID: 27568453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivastigmine improves dual-task gait velocity in patients with Alzheimer's disease.
    Shimura H; Saiko A; Hayashi A; Hattori N; Urabe T
    BMC Neurol; 2021 Feb; 21(1):61. PubMed ID: 33568083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-dementia drugs-related changes in gait performance while single and dual tasking in patients with Alzheimer disease: a meta-analysis.
    Beauchet O; Launay CP; Montero-Odasso M; Annweiler C; Allali G
    Curr Alzheimer Res; 2015; 12(8):761-71. PubMed ID: 26159199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in gait variability with anti-dementia drugs: a systematic review and meta-analysis.
    Beauchet O; Launay CP; Allali G; Annweiler C
    CNS Drugs; 2014 Jun; 28(6):513-8. PubMed ID: 24806974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
    Noetzli M; Eap CB
    Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donepezil improves gait performance in older adults with mild Alzheimer's disease: a phase II clinical trial.
    Montero-Odasso M; Muir-Hunter SW; Oteng-Amoako A; Gopaul K; Islam A; Borrie M; Wells J; Speechley M
    J Alzheimers Dis; 2015; 43(1):193-9. PubMed ID: 25079803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of executive function on locomotor function: divided attention increases gait variability in Alzheimer's disease.
    Sheridan PL; Solomont J; Kowall N; Hausdorff JM
    J Am Geriatr Soc; 2003 Nov; 51(11):1633-7. PubMed ID: 14687395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dual-tasking on walking and cognitive demands in adults with Alzheimer's dementia experienced in using a 4-wheeled walker.
    Hunter SW; Omana H; Madou E; Wittich W; Hill KD; Johnson AM; Divine A; Holmes JD
    Gait Posture; 2020 Mar; 77():164-170. PubMed ID: 32044696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical training-related changes in gait variability while single and dual tasking in older adults: magnitude of gait variability at baseline matters.
    Beauchet O; Launay C; Annweiler C; Fantino B; Allali G; De Decker L
    Eur J Phys Rehabil Med; 2013 Dec; 49(6):857-64. PubMed ID: 24285023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of impaired executive function on gait stability.
    Allali G; Assal F; Kressig RW; Dubost V; Herrmann FR; Beauchet O
    Dement Geriatr Cogn Disord; 2008; 26(4):364-9. PubMed ID: 18852489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor cortex and gait in mild cognitive impairment: a magnetic resonance spectroscopy and volumetric imaging study.
    Annweiler C; Beauchet O; Bartha R; Wells JL; Borrie MJ; Hachinski V; Montero-Odasso M
    Brain; 2013 Mar; 136(Pt 3):859-71. PubMed ID: 23436505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gait and risk of falls associated with frontal cognitive functions at different stages of Alzheimer's disease.
    Coelho FG; Stella F; de Andrade LP; Barbieri FA; Santos-Galduróz RF; Gobbi S; Costa JL; Gobbi LT
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2012 Sep; 19(5):644-56. PubMed ID: 22360785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).
    Matsuzono K; Yamashita T; Ohta Y; Hishikawa N; Sato K; Kono S; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 46(3):687-93. PubMed ID: 26402513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.